Pfizer, Inc. (PFE) stock still looks cheap ahead of its upcoming Aug. 5 Q2 earnings release. Moreover, investors can make extra income by selling out-of-the-money (OTM) put options. This article ...

Wall Street expects a year-over-year decline in earnings on higher revenues when Pfizer (PFE) reports results for the quarter ...

Pfizer Inc. (NYSE:PFE) is among the 12 Best Ethical Companies to Invest in 2025. On July 24, 2025, Pfizer Inc. (NYSE:PFE) ...

BioNTech SE and Pfizer (PFE) recently received a positive recommendation from the European Medicines Agency for marketing ...

Pfizer is cutting costs, growing its core business, and trading at a deep discount despite looming patent losses and COVID ...

Pfizer has an analyst consensus of Hold, with a price target consensus of $28.50, implying a 14.97% upside from current levels. In a report released yesterday, Bernstein also maintained a Hold rating ...

Pfizer (NYSE:PFE) is one of the world’s largest pharmaceutical companies, but at $22.59 per share as of this writing, the stock trades at its lowest levels in 13 years. Shares are down 19% over ...

Pfizer reported revenues of $13.72 billion in the last reported quarter, representing a year-over-year change of -7.8%. EPS of $0.92 for the same period compares with $0.82 a year ago.

Within the past year, PFE's PEG has been as high as 1.24 and as low as 0.56, with a median of 0.97. Value investors also love the P/S ratio, which is calculated by simply dividing a stock's price ...

Pfizer Inc. (NYSE:PFE) hasn’t performed well in recent years, with its stock declining more than 26% over the past decade.

Pfizer (PFE) stock in focus as company faces lawsuits over its alleged failure to warn about brain tumor risks linked to Depo ...